BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fukui H, Wiest R. Changes of Intestinal Functions in Liver Cirrhosis. Inflamm Intest Dis. 2016;1:24-40. [PMID: 29922655 DOI: 10.1159/000444436] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Liang Y, Ming Q, Liang J, Zhang Y, Zhang H, Shen T. Gut microbiota dysbiosis in polycystic ovary syndrome: association with obesity - a preliminary report. Can J Physiol Pharmacol. 2020;98:803-809. [PMID: 32150694 DOI: 10.1139/cjpp-2019-0413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
2 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
3 Meyer F, Bannert K, Wiese M, Esau S, Sautter LF, Ehlers L, Aghdassi AA, Metges CC, Garbe LA, Jaster R, Lerch MM, Lamprecht G, Valentini L. Molecular Mechanism Contributing to Malnutrition and Sarcopenia in Patients with Liver Cirrhosis. Int J Mol Sci 2020;21:E5357. [PMID: 32731496 DOI: 10.3390/ijms21155357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
4 Besler C, Unterhuber M, Rommel K, Unger E, Hartung P, Roeder M, Noack T, Zachäus M, Halm U, Borger M, Desch S, Thiele H, Lurz P. Nutritional status in tricuspid regurgitation: implications of transcatheter repair. Eur J Heart Fail 2020;22:1826-36. [DOI: 10.1002/ejhf.1752] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
5 Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol 2020;115:165-78. [PMID: 32023228 DOI: 10.14309/ajg.0000000000000501] [Cited by in Crossref: 60] [Cited by in F6Publishing: 41] [Article Influence: 30.0] [Reference Citation Analysis]
6 Cresci GAM. Is It Time to Consider Gut Microbiome Readouts for Precision Diagnosis and Treatment of Alcoholic Liver Disease? Hepatology 2020;72:4-6. [PMID: 32198889 DOI: 10.1002/hep.31245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World J Hepatol 2019; 11(6): 489-512 [PMID: 31293718 DOI: 10.4254/wjh.v11.i6.489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
8 Kumar R, Anand U, Priyadarshi RN. Lymphatic dysfunction in advanced cirrhosis: Contextual perspective and clinical implications. World J Hepatol 2021; 13(3): 300-314 [PMID: 33815674 DOI: 10.4254/wjh.v13.i3.300] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li YT, Huang JR, Peng ML. Current Status and Prospects of Spontaneous Peritonitis in Patients with Cirrhosis. Biomed Res Int 2020;2020:3743962. [PMID: 32724800 DOI: 10.1155/2020/3743962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ren X, Di Z, Zhang Z, Fu B, Wang Y, Huang C, Du Y. Chinese herbal medicine for the treatment of small intestinal bacterial overgrowth (SIBO): A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23737. [PMID: 33371127 DOI: 10.1097/MD.0000000000023737] [Reference Citation Analysis]
11 Ghufran A. Nutrition in Chronic Liver Disease: A Point-of-Care Review. Nutr Clin Pract. 2020;35:211-217. [PMID: 32092183 DOI: 10.1002/ncp.10470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liu J, Xu Y, Jiang B. Novel Insights Into Pathogenesis and Therapeutic Strategies of Hepatic Encephalopathy, From the Gut Microbiota Perspective. Front Cell Infect Microbiol 2021;11:586427. [PMID: 33692964 DOI: 10.3389/fcimb.2021.586427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
14 Ehlers L, Bannert K, Rohde S, Berlin P, Reiner J, Wiese M, Doller J, Lerch MM, Aghdassi AA, Meyer F, Valentini L, Agrifoglio O, Metges CC, Lamprecht G, Jaster R. Preclinical insights into the gut-skeletal muscle axis in chronic gastrointestinal diseases. J Cell Mol Med 2020;24:8304-14. [PMID: 32628812 DOI: 10.1111/jcmm.15554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front Immunol 2019;10:293. [PMID: 30873165 DOI: 10.3389/fimmu.2019.00293] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
16 Mollar A, Villanueva MP, NÚÑez E, CarratalÁ A, Mora F, BayÉs-GenÍs A, MÍnguez M, Marrachelli VG, Monleon D, Navarro D, Sanchis J, NÚÑez J. Hydrogen- and Methane-Based Breath Testing and Outcomes in Patients With Heart Failure. J Card Fail 2019;25:319-27. [PMID: 30347272 DOI: 10.1016/j.cardfail.2018.10.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
17 Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72:320-341. [PMID: 31954495 DOI: 10.1016/j.jhep.2019.10.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 40.0] [Reference Citation Analysis]
18 Ommati MM, Farshad O, Mousavi K, Jamshidzadeh A, Azmoon M, Heidari S, Azarpira N, Niknahad H, Heidari R. Betaine supplementation mitigates intestinal damage and decreases serum bacterial endotoxin in cirrhotic rats. PharmaNutrition 2020;12:100179. [DOI: 10.1016/j.phanu.2020.100179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Gundling F, Luxi M, Seidel H, Schepp W, Schmidt T. Small intestinal dysmotility in cirrhotic patients: correlation with severity of liver disease and cirrhosis-associated complications. Z Gastroenterol 2021;59:540-50. [PMID: 32512591 DOI: 10.1055/a-1162-0357] [Reference Citation Analysis]
20 Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021;75 Suppl 1:S67-81. [PMID: 34039493 DOI: 10.1016/j.jhep.2020.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Loisios-Konstantinidis I, Dressman J. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of In Vivo Clinical Studies: Current Status, Challenges, and Opportunities. Mol Pharm 2021;18:1-17. [PMID: 33320002 DOI: 10.1021/acs.molpharmaceut.0c00903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Hassouneh R, Bajaj JS. Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. J Clin Med 2021;10:330. [PMID: 33477417 DOI: 10.3390/jcm10020330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
23 Vairetti M, Di Pasqua LG, Cagna M, Richelmi P, Ferrigno A, Berardo C. Changes in Glutathione Content in Liver Diseases: An Update. Antioxidants (Basel) 2021;10:364. [PMID: 33670839 DOI: 10.3390/antiox10030364] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
24 Bellar A, Welch N, Dasarathy S. Exercise and physical activity in cirrhosis: opportunities or perils. J Appl Physiol (1985) 2020;128:1547-67. [PMID: 32240017 DOI: 10.1152/japplphysiol.00798.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]